Meng, Min
Liu, Enmei
Zhang, Bo
Lu, Quan
Zhang, Xiaobo
Ge, Bin
Wu, Ye
Wang, Li
Wang, Mo
Luo, Zhengxiu
Hua, Ziyu
Wang, Xiaoling
Zhao, Wei
Zheng, Yi
Wu, Xinan
Zhao, Ruiling
Meng, Wenbo
Xiang, Li
Wang, Gang
Jia, Yuntao
Chen, Yongchuan
Dong, Xiaoyan
Hao, Lina
Liu, Chengjun
Lv, Meng
Luo, Xufei
Liu, Yunlan
Shen, Quan
Lei, Wenjuan
Wang, Ping
Sun, Yajia
Zhang, Juanjuan
Wang, Ling
Lei, Ruobing
Hou, Tianchun
Yang, Bo
Li, Qiu
Chen, Yaolong
Article History
Received: 6 March 2022
Accepted: 27 June 2022
First Online: 23 July 2022
Declarations
:
: The study/development of guidelines were approved by the Chinese Society of Pediatric Clinical Pharmacology, the Chinese Medical Association, the National Clinical Medical Research Center for Child Health and Disease (Children's Hospital of Chongqing Medical University), and the Chinese GRADE Center. Participation of all participants were voluntarily and they were informed about the objective of the study. All members completed a declaration of interest form and stated that they had no economic conflicts of interest directly relevant to this guideline. All methods were carried out in relevant regulations and guidelines.
: Not applicable.
: The authors declare that they have no competing interests.